ZEALAND PHARMA A/S reported a Q1 operating loss of 539 million Danish crowns ($85 million), beating analyst estimates of 672.4 million crowns. The Denmark-based developer also announced a $200 million share buyback following positive clinical progress in its obesity drug pipeline. Results exceeded forecasts as the company advanced its obesity drug candidates.
Zealand Pharma reports smaller Q1 loss and share buyback
Zealand Pharma reported a smaller Q1 loss of 539 million Danish crowns as its obesity pipeline advances. The company also launched a $200 million buyback.
Xurve View
洞察:
Xurve View
### Pipeline Progress Drives Financial Outperformance Zealand's operating loss was 133.4 million crowns narrower than the LSEG-compiled forecast on Thursday morning. CEO Adam Steensberg said advancements in the obesity portfolio during the quarter helped Zealand strengthen its long-term guidance.











